Drug Trial Radar · NCT03624322
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
Last checked: Nov 19, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Aug 5, 2018
Primary completion
Oct 3, 2018
Study completion Oct 3, 2018
Sponsor
- Lead sponsor
- Impel PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a Precision Olfactory Delivery (POD®) nasal spray device (I231 POD® Device). The proposed indication for INP105 is the treatment of acute agitation associated with schizophrenia and bipolar I disorder.
Conditions
- Acute Agitation
Interventions
Zyprexa IMDrug
5mg
ZydisDrug
10mg orally disintegrating wafer
INP105Drug
Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)
I231 POD® DeviceDevice
Precision Olfactory Delivery (POD) device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: 30 days
- PK profile of OLZ INP105 TmaxTime frame: 72 hours
- PK profile of OLZ INP105 CmaxTime frame: 72 hours
- PK profile of Zyprexa IM TmaxTime frame: 72 hours
- PK profile of Zyprexa IM CmaxTime frame: 72 hrs
- PK profile of Zyprexa Zydis TmaxTime frame: 72 hours
- PK profile of Zyprexa Zydis CmaxTime frame: 72 hours
- PD effects of INP105 vs placeboTime frame: 72 hours
- PD effects of Zyprexa IMTime frame: 72 hours
- PD effects of Zyprexa ZydisTime frame: 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.